Atherosclerosis regression and high-density lipoproteins

References

• Ross R. Atherosclerosis – an inflammatory disease. N. Engl. J. Med.340, 115–126 (1999).
   PubMed Web of Science ®Google Scholar
• Small DM, Bond MG, Waugh D et al. Physicochemical and histological changes in the arterial wall of nonhuman primates during progression and regression of atherosclerosis. J. Clin. Invest.73, 1590–1605 (1984).
   Google Scholar
• Badimon J, Badimon L, Fuster V. Regression of atherosclerotic lesions by high density lipoprotein plasma fraction in the cholesterol-fed rabbit. J. Clin. Invest.85, 1234–1241 (1990).
   PubMed Web of Science ®Google Scholar
• Plump AS, Smith JD, Hayek T et al. Severe hypercholesterolemia and atherosclerosis in Apolipoprotein E-deficient mice created by homologous recombination in ES cells. Cell 71, 343–353 (1992).
   PubMed Web of Science ®Google Scholar
• Kashyap VS, Santamarina-Fojo S, Brown DR et al. Apolipoprotein E deficiency in mice: gene replacement and prevention of atherosclerosis using adenovirus vectors. J. Clin. Invest.96, 1612–1620 (1995).
   PubMed Web of Science ®Google Scholar
• Reis ED, Li J, Fayad ZA et al. Dramatic remodeling of advanced atherosclerotic plaques of the Apolipoprotein E-deficient mouse in a novel transplantation model. J. Vasc. Surg.34, 541–547 (2001).
   PubMed Web of Science ®Google Scholar
• Grundy SM, Cleeman JI, Merz CNB et al. Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. Arterioscler. Thromb. Vasc. Biol.24, e149–e161 (2004).
   PubMed Web of Science ®Google Scholar
• MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial. Lancet360, 7–22 (2002).
   PubMed Web of Science ®Google Scholar
• Gordon T, Castelli WP, Hjortland MC et al. High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am. J. Med.62, 707–714 (1977).
   PubMed Web of Science ®Google Scholar
• Gordon DJ, Probstfield JL, Garrison RJ et al. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation79, 8–15 (1989).
   PubMed Web of Science ®Google Scholar
• Assmann G, Schulte H. Relation of high-density lipoprotein cholesterol and triglycerides to incidence of atherosclerotic coronary artery disease (the PROCAM Experience). Prospective Cardiovascular Munster study. Am. J. Cardiol.70, 733–737 (1992).
   PubMed Web of Science ®Google Scholar
• Grundy SM, Cleeman JI, Daniels SR et al. diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement: Executive Summary. Circulation112, e285–e290 (2005).
   Google Scholar
• Dekker JM, Girman C, Rhodes T et al. Metabolic syndrome and 10-year cardiovascular disease risk in the Hoorn Study. Circulation112, 666–673 (2005).
   PubMed Web of Science ®Google Scholar
• Haffner SM, Lehto S, Ronnemaa T et al. Mortality from coronary heart disease in subjects with Type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N. Engl. J. Med.339, 229 (1998).
   PubMed Web of Science ®Google Scholar
• Zimmet P, Alberti KG, Shaw J. Global and societal implications of the diabetes epidemic. Nature414, 782–787 (2001).
   PubMed Web of Science ®Google Scholar
• Bruckert E, Baccara-Dinet M, McCoy F et al. High prevalence of low HDL-cholesterol in a pan-European survey of 8545 dyslipidaemic patients. Curr. Med. Res. Opin.21, 1927–1934 (2005).
   PubMed Web of Science ®Google Scholar
• Nichols GA, Ambegaonkar BM, Sazonov V et al. Frequency of obtaining National Cholesterol Education Program Adult Treatment Panel III goals for all major serum lipoproteins after initiation of lipid altering therapy. Am. J. Cardiol.104, 1689–1694 (2009).
   PubMed Web of Science ®Google Scholar
• Grover SA, Kaouache M, Joseph L et al. Evaluating the incremental benefits of raising high-density lipoprotein cholesterol levels during lipid therapy after adjustment for the reductions in other blood lipid levels. Arch. Intern. Med.169, 1775–1780 (2009).
   PubMedGoogle Scholar
• Miyazaki A, Rahim ATMA, Ohta T et al. High density lipoprotein mediates selective reduction in cholesteryl esters from macrophage foam cells. Biochim. Biophys. Acta1126, 73 (1992).
   Google Scholar
• Oram JF, Lawn RM. ABCA1. The gatekeeper for eliminating excess tissue cholesterol. J. Lipid. Res.42, 1173–1179 (2001).
   PubMed Web of Science ®Google Scholar
• Gelissen IC, Harris M, Rye K-A et al. ABCA1 and ABCG1 synergize to mediate cholesterol export to ApoA-I. Arterioscler. Thromb. Vasc. Biol.26(3), 534–540 (2005).
   Google Scholar
• Rubin EM, Krauss RM, Spangler EA et al. Inhibition of early atherogenesis in transgenic mice by human apolipoprotein AI. Nature353, 265–267 (1991).
   PubMed Web of Science ®Google Scholar
• Rong JX, Li J, Reis ED et al. Elevating high-density lipoprotein cholesterol in Apolipoprotein E-deficient mice remodels advanced atherosclerotic lesions by decreasing macrophage and increasing smooth muscle cell content. Circulation104, 2447–2452 (2001).
   PubMed Web of Science ®Google Scholar
• Choudhury RP, Rong JX, Trogan E et al. High-density lipoproteins retard the progression of atherosclerosis and favorably remodel lesions without suppressing indices of inflammation or oxidation. Arterioscler. Thromb. Vasc. Biol.24, 1904–1909 (2004).
   Google Scholar
• Llodra J, Angeli V, Liu J et al. Emigration of monocyte-derived cells from atherosclerotic lesions characterizes regressive, but not progressive, plaques. Proc. Natl Acad. Sci. USA101, 11779–11784 (2004).
   PubMed Web of Science ®Google Scholar
• Trogan E, Feig JE, Dogan S et al. Gene expression changes in foam cells and the role of chemokine receptor CCR7 during atherosclerosis regression in ApoE-deficient mice. Proc. Natl Acad. Sci. USA103, 3781–3786 (2006).
   PubMed Web of Science ®Google Scholar
• Cockerill GW, Rye KA, Gamble JR et al. High-density lipoproteins inhibit cytokine-induced expression of endothelial cell adhesion molecules. Arterioscler. Thromb. Vasc. Biol.15, 1987–1994 (1995).
   PubMed Web of Science ®Google Scholar
• Nicholls SJ, Cutri B, Worthley SG et al. Impact of short-term administration of high-density lipoproteins and atorvastatin on atherosclerosis in rabbits. Arterioscler. Thromb. Vasc. Biol.25, 2416–2421 (2005).
   PubMed Web of Science ®Google Scholar
• Nicholls SJ, Dusting GJ, Cutri B et al. Reconstituted high-density lipoproteins inhibit the acute pro-oxidant and proinflammatory vascular changes induced by a periarterial collar in normocholesterolemic rabbits. Circulation111, 1543–1550 (2005).
   PubMed Web of Science ®Google Scholar
• Fogelman AM, Shechter I, Seager J et al. Malondialdehyde alteration of low density lipoproteins leads to cholesteryl ester accumulation in human monocyte-macrophages. Proc. Natl Acad. Sci. USA77, 2214–2218 (1980).
   PubMed Web of Science ®Google Scholar
• Watson AD, Berliner JA, Hama SY et al. Protective effect of high density lipoprotein associated paraoxonase. Inhibition of the biological activity of minimally oxidized low density lipoprotein. J. Clin. Invest.96, 2882–2891 (1995).
   PubMed Web of Science ®Google Scholar
• Mackness MI, Arrol S, Durrington PN. Paraoxonase prevents accumulation of lipoperoxides in low-density lipoprotein. FEBS Lett.286, 152 (1991).
   PubMed Web of Science ®Google Scholar
• Garner B, Waldeck AR, Witting PK et al. Oxidation of High Density Lipoproteins. II. Evidence for direct reduction of lipid hydroperoxides by methionine residues of Apolipoprotetins AI and AII. J. Biol. Chem.273, 6088–6095 (1998).
   PubMed Web of Science ®Google Scholar
• Glagov S, Weisenberg E, Zarins CK et al. Compensatory enlargement of human atherosclerotic coronary arteries. N. Engl. J. Med.316, 1371–1375 (1987).
   PubMed Web of Science ®Google Scholar
• Blankenhorn DH, Nessim SA, Johnson RL et al. Beneficial effects of combined colestipol–niacin therapy on coronary atherosclerosis and coronary venous bypass grafts. JAMA257, 3233–3240 (1987).
   PubMed Web of Science ®Google Scholar
• Cashin-Hemphill L, Mack WJ, Pogoda JM et al. Beneficial effects of colestipol-niacin on coronary atherosclerosis. A 4-year follow-up. JAMA264, 3013–3017 (1990).
   PubMed Web of Science ®Google Scholar
• Brown G, Albers JJ, Fisher LD et al. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N. Engl. J. Med.323, 1289–1298 (1990).
   PubMed Web of Science ®Google Scholar
• Brown BG, Zhao X-Q, Chait A et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N. Engl. J. Med.345, 1583–1592 (2001).
   PubMed Web of Science ®Google Scholar
• Whitney EJ, Krasuski RA, Personius BE et al. A randomized trial of a strategy for increasing high-density lipoprotein cholesterol levels: effects on progression of coronary heart disease and clinical events. Ann. Intern. Med.142, 95–104 (2005).
   PubMed Web of Science ®Google Scholar
• Topol EJ, Nissen SE. Our preoccupation with coronary luminology. The dissociation between clinical and angiographic findings in ischemic heart disease. Circulation92, 2333–2342 (1995).
   PubMed Web of Science ®Google Scholar
• Bots ML, Evans GW, Riley WA et al. Carotid intima–media thickness measurements in intervention studies: design options, progression rates, and sample size considerations: a point of view. Stroke34, 2985–2994 (2003).
   PubMed Web of Science ®Google Scholar
• Nissen SE, Tsunoda T, Tuzcu EM et al. Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. JAMA290, 2292–2300 (2003).
   PubMed Web of Science ®Google Scholar
• Nissen SE, Tardif JC, Nicholls SJ et al. Effect of torcetrapib on the progression of coronary atherosclerosis. N. Engl. J. Med.356, 1304–1316 (2007).
   PubMed Web of Science ®Google Scholar
• Nissen SE, Nicholls SJ, Wolski K et al. Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with Type 2 diabetes: the PERISCOPE randomized controlled trial. JAMA299, 1561–1573 (2008).
   PubMed Web of Science ®Google Scholar
• Corti R, Fayad ZA, Fuster V et al. Effects of lipid-lowering by simvastatin on human atherosclerotic lesions: a longitudinal study by high-resolution, noninvasive magnetic resonance imaging. Circulation104, 249–252 (2001).
   PubMed Web of Science ®Google Scholar
• Lee JM, Wiesmann F, Shirodaria C et al. Early changes in arterial structure and function following statin initiation: quantification by magnetic resonance imaging. Atherosclerosis197, 951–958 (2008).
   Google Scholar
• Saam T, Kerwin WS, Chu B et al. Sample size calculation for clinical trials using magnetic resonance imaging for the quantitative assessment of carotid atherosclerosis. J. Cardiovasc. Magn. Reson.7, 799–808 (2005).
   PubMed Web of Science ®Google Scholar
• Varghese A, Crowe LA, Mohiaddin RH et al. Interstudy reproducibility of three-dimensional volume-selective fast spin echo magnetic resonance for quantifying carotid artery wall volume. J. Magn. Reson. Imag.21, 187–191 (2005).
   PubMed Web of Science ®Google Scholar
• Duivenvoorden R, de Groot E, Elsen BM et al.In vivo quantification of carotid artery wall dimensions: 3.0-Tesla MRI versus B-mode ultrasound imaging. Circ. Cardiovasc. Imag.2, 235–242 (2009).
   PubMed Web of Science ®Google Scholar
• Yuan C, Mitsumori LM, Beach KW et al. Carotid atherosclerotic plaque: noninvasive MR characterization and identification of vulnerable lesions. Radiology221, 285–299 (2001).
   PubMed Web of Science ®Google Scholar
• Saam T, Ferguson MS, Yarnykh VL et al. Quantitative evaluation of carotid plaque composition by in vivo MRI. Arterioscler. Thromb. Vasc. Biol.25, 234–239 (2005).
   PubMed Web of Science ®Google Scholar
• Zhao X-Q, Yuan C, Hatsukami TS et al. Effects of prolonged intensive lipid-lowering therapy on the characteristics of carotid atherosclerotic plaques in vivo by MRI: a case–control study. Arterioscler. Thromb. Vasc. Biol.21, 1623–1629 (2001).
   PubMed Web of Science ®Google Scholar
• Underhill HR, Yuan C, Zhao XQ et al. Effect of rosuvastatin therapy on carotid plaque morphology and composition in moderately hypercholesterolemic patients: a high-resolution magnetic resonance imaging trial. Am. Heart J.155, 584.e1–8 (2008).
   Web of Science ®Google Scholar
• Prati F, Regar E, Mintz GS et al. Expert review document on methodology, terminology, and clinical applications of optical coherence tomography: physical principles, methodology of image acquisition, and clinical application for assessment of coronary arteries and atherosclerosis. Eur. Heart J.31, 401–415 (2009).
   Google Scholar
• Rudd JH, Myers KS, Bansilal S et al.18Fluorodeoxyglucose positron emission tomography imaging of atherosclerotic plaque inflammation is highly reproducible: implications for atherosclerosis therapy trials. J. Am. Coll. Cardiol.50, 892–896 (2007).
   PubMed Web of Science ®Google Scholar
• No authors listed. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet344, 1383–1389 (1994).
   PubMed Web of Science ®Google Scholar
• Baigent C, Keech A, Kearney PM et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet366, 1267–1278 (2005).
   PubMed Web of Science ®Google Scholar
• Wierzbicki AS, Mikhailidis DP. Dose-response effects of atorvastatin and simvastatin on high-density lipoprotein cholesterol in hypercholesterolaemic patients: a review of five comparative studies. Int. J. Cardiol.84, 53–57 (2002).
   PubMed Web of Science ®Google Scholar
• Taylor AJ, Kent SM, Flaherty PJ et al. ARBITER: Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol: a randomized trial comparing the effects of atorvastatin and pravastatin on carotid intima medial thickness. Circulation106, 2055–2060 (2002).
   PubMed Web of Science ®Google Scholar
• de Groot E, Jukema JW, Montauban van Swijndregt AD et al. B-mode ultrasound assessment of pravastatin treatment effect on carotid and femoral artery walls and its correlations with coronary arteriographic findings: a report of the Regression Growth Evaluation Statin Study (REGRESS). J. Am. Coll. Cardiol.31, 1561–1567 (1998).
   PubMed Web of Science ®Google Scholar
• Nissen SE, Tuzcu EM, Schoenhagen P et al. Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. N. Engl. J. Med.352, 29–38 (2005).
   PubMed Web of Science ®Google Scholar
• Nissen SE, Nicholls SJ, Sipahi I et al. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA295, 1556–1565 (2006).
   PubMed Web of Science ®Google Scholar
• Nicholls SJ, Tuzcu EM, Sipahi I et al. Statins, high-density lipoprotein cholesterol, and regression of coronary atherosclerosis. JAMA297, 499–508 (2007).
   PubMed Web of Science ®Google Scholar
• Altschul R, Hoffer A, Stephen JD. Influence of nicotinic acid on serum cholesterol in man. Arch. Biochem.54, 558–559 (1955).
   PubMed Web of Science ®Google Scholar
• Morgan JM, Capuzzi DM, Guyton JR et al. Treatment effect of Niaspan, a controlled-release niacin, in patients with hypercholesterolemia: a placebo-controlled trial. J. Cardiovasc. Pharmacol. Ther.1, 195–202 (1996).
   PubMedGoogle Scholar
• Morgan J, Capuzzi D, Guyton J. A new extended-release niacin (Niaspan): efficacy, tolerability, and safety in hypercholesterolemic patients. Am. J. Cardiol.82, 29U–34U (1998).
   PubMed Web of Science ®Google Scholar
• Tunaru S, Kero J, Schaub A et al. PUMA-G and HM74 are receptors for nicotinic acid and mediate its anti-lipolytic effect. Nat. Med.9, 352–355 (2003).
   PubMed Web of Science ®Google Scholar
• van der Hoorn JW, de Haan W, Berbee JF et al. Niacin increases HDL by reducing hepatic expression and plasma levels of cholesteryl ester transfer protein in APOE*3Leiden.CETP mice. Arterioscler. Thromb. Vasc. Biol.28, 2016–2022 (2008).
   PubMed Web of Science ®Google Scholar
• Ganji SH, Tavintharan S, Zhu D et al. Niacin noncompetitively inhibits DGAT2 but not DGAT1 activity in HepG2 cells. J. Lipid. Res.45, 1835–1845 (2004).
   PubMed Web of Science ®Google Scholar
• Jin FY, Kamanna VS, Kashyap ML. Niacin accelerates intracellular ApoB degradation by inhibiting triacylglycerol synthesis in human hepatoblastoma (HepG2) cells. Arterioscler. Thromb. Vasc. Biol.19, 1051–1059 (1999).
   PubMed Web of Science ®Google Scholar
• Shepherd J, Packard CJ, Patsch JR et al. Effects of nicotinic acid therapy on plasma high density lipoprotein subfraction distribution and composition and on Apolipoprotein A metabolism. J. Clin. Invest.63, 858–867 (1979).
   PubMed Web of Science ®Google Scholar
• Jin F-Y, Kamanna VS, Kashyap ML. Niacin decreases removal of high-density lipoprotein apolipoprotein A-I but not cholesterol ester by Hep G2 cells: implication for reverse cholesterol transport. Arterioscler. Thromb. Vasc. Biol.17, 2020–2028 (1997).
   PubMed Web of Science ®Google Scholar
• Martinez LO, Jacquet S, Esteve JP et al. Ectopic β-chain of ATP synthase is an apolipoprotein A-I receptor in hepatic HDL endocytosis. Nature421, 75–79 (2003).
   PubMed Web of Science ®Google Scholar
• Zhang LH, Kamanna VS, Zhang MC et al. Niacin inhibits surface expression of ATP synthase β chain in HepG2 cells: implications for raising HDL. J. Lipid. Res.49, 1195–1201 (2008).
   PubMed Web of Science ®Google Scholar
• Rubic T, Trottmann M, Lorenz RL. Stimulation of CD36 and the key effector of reverse cholesterol transport ATP-binding cassette A1 in monocytoid cells by niacin. Biochem. Pharmacol.67, 411–419 (2004).
   PubMed Web of Science ®Google Scholar
• Knowles HJ, te Poele RH, Workman P et al. Niacin induces PPARγ expression and transcriptional activation in macrophages via HM74 and HM74a-mediated induction of prostaglandin synthesis pathways. Biochem. Pharmacol.71, 646–656 (2006).
   PubMedGoogle Scholar
• Taylor AJ, Sullenberger LE, Lee HJ et al. Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation110, 3512–3517 (2004).
   PubMed Web of Science ®Google Scholar
• Lee JM, Robson MD, Yu LM et al. Effects of high-dose modified-release nicotinic acid on atherosclerosis and vascular function: a randomized, placebo-controlled, magnetic resonance imaging study. J. Am. Coll. Cardiol.54, 1787–1794 (2009).
   PubMed Web of Science ®Google Scholar
• Taylor AJ, Villines TC, Stanek EJ et al. Extended-release niacin or ezetimibe and carotid intima–media thickness. N. Engl. J. Med.361, 2113–2122 (2009).
   PubMed Web of Science ®Google Scholar
• Canner PL, Berge KG, Wenger NK et al. Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. J. Am. Coll. Cardiol.8, 1245–1255 (1986).
   PubMed Web of Science ®Google Scholar
• Rubins HB, Robins SJ, Collins D et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N. Engl. J. Med.341, 410–418 (1999).
   PubMed Web of Science ®Google Scholar
• No authors listed. Secondary Prevention by raising HDL Cholesterol and reducing triglycerides in patients with coronary artery disease: the Bezafibrate Infarction Prevention (BIP) Study. Circulation102, 21–27 (2000).
   PubMed Web of Science ®Google Scholar
• Keech A, Simes RJ, Barter P et al.; FIELD study investigators. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with Type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet366, 1849 (2005).
   PubMed Web of Science ®Google Scholar
• Ginsberg HN, Elam MB, Lovato LC et al. Effects of combination lipid therapy in Type 2 diabetes mellitus. N. Engl. J. Med.362, 1563–1574 (2010).
   PubMed Web of Science ®Google Scholar
• Hiukka A, Westerbacka J, Leinonen ES et al. Long-term effects of fenofibrate on carotid intima–media thickness and augmentation index in subjects with Type 2 diabetes mellitus. J. Am. Coll. Cardiol.52, 2190–2197 (2008).
   PubMed Web of Science ®Google Scholar
• Ayaori M, Momiyama Y, Fayad ZA et al. Effect of bezafibrate therapy on atherosclerotic aortic plaques detected by MRI in dyslipidemic patients with hypertriglyceridemia. Atherosclerosis196, 425–433 (2008).
   Google Scholar
• Dormandy JA, Charbonnel B, Eckland DJ et al. Secondary prevention of macrovascular events in patients with Type 2 diabetes in the PROactive Study (Prospective Pioglitazone Clinical Trial in Macrovascular Events): a randomised controlled trial. Lancet366, 1279 (2005).
   PubMed Web of Science ®Google Scholar
• Freed MI, Ratner R, Marcovina SM et al. Effects of rosiglitazone alone and in combination with atorvastatin on the metabolic abnormalities in Type 2 diabetes mellitus. Am. J. Cardiol.90, 947 (2002).
   PubMed Web of Science ®Google Scholar
• Goldberg RB, Kendall DM, Deeg MA et al. A Comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with Type 2 diabetes and dyslipidemia. Diabetes Care28, 1547–1554 (2005).
   PubMed Web of Science ®Google Scholar
• Sidhu JS, Kaposzta Z, Markus HS et al. Effect of rosiglitazone on common carotid intima–media thickness progression in coronary artery disease patients without diabetes mellitus. Arterioscler. Thromb. Vasc. Biol.24, 930–934 (2004).
   PubMed Web of Science ®Google Scholar
• Varghese A, Yee MS, Chan CF et al. Effect of rosiglitazone on progression of atherosclerosis: insights using 3D carotid cardiovascular magnetic resonance. J. Cardiovasc. Magn. Reson.11, 24 (2009).
   Google Scholar
• Brousseau ME, Schaefer EJ, Wolfe ML et al. Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol. N. Engl. J. Med.350, 1505–1515 (2004).
   PubMed Web of Science ®Google Scholar
• Okamoto H, Yonemori F, Wakitani K et al. A cholesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbits. Nature406, 203–207 (2000).
   PubMed Web of Science ®Google Scholar
• Ordovas JM, Cupples LA, Corella D et al. Association of cholesteryl ester transfer protein-TaqIB polymorphism with variations in lipoprotein subclasses and coronary heart disease risk: the Framingham study. Arterioscler. Thromb. Vasc. Biol.20, 1323–1329 (2000).
   PubMed Web of Science ®Google Scholar
• Thompson A, Di Angelantonio E, Sarwar N et al. Association of cholesteryl ester transfer protein genotypes with CETP mass and activity, lipid levels, and coronary risk. JAMA299, 2777–2788 (2008).
   PubMed Web of Science ®Google Scholar
• Zhong S, Sharp DS, Grove JS et al. Increased coronary heart disease in japanese-american men with mutation in the cholesteryl ester transfer protein gene despite increased HDL levels. J. Clin. Invest.97, 2917–2923 (1996).
   PubMed Web of Science ®Google Scholar
• Duwensee K, Breitling LP, Tancevski I et al. Cholesteryl ester transfer protein in patients with coronary heart disease. Eur. J. Clin. Invest.40(7), 616–622 (2010).
   PubMed Web of Science ®Google Scholar
• Barter PJ, Caulfield M, Eriksson M et al. Effects of torcetrapib in patients at high risk for coronary events. N. Engl. J. Med.357, 2109–2122 (2007).
   PubMed Web of Science ®Google Scholar
• Bots ML, Visseren FL, Evans GW et al. Torcetrapib and carotid intima–media thickness in mixed dyslipidaemia (RADIANCE 2 study): a randomised, double-blind trial. Lancet370, 153–160 (2007).
   PubMed Web of Science ®Google Scholar
• Kastelein JJ, van Leuven SI, Burgess L et al. Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia. N. Engl. J. Med.356, 1620–1630 (2007).
   PubMed Web of Science ®Google Scholar
• Schwartz GG, Olsson AG, Ballantyne CM et al. Rationale and design of the dal-OUTCOMES trial: efficacy and safety of dalcetrapib in patients with recent acute coronary syndrome. Am. Heart J.158, 896–901.e3 (2009).
   PubMed Web of Science ®Google Scholar
• Stein EA, Stroes ES, Steiner G et al. Safety and tolerability of dalcetrapib. Am. J. Cardiol.104, 82–91 (2009).
   PubMed Web of Science ®Google Scholar
• Ranalletta M, Bierilo KK, Chen Y et al. Biochemical characterization of cholesteryl ester transfer protein inhibitors. J. Lipid Res.51, 2739–2752 (2010).
   PubMed Web of Science ®Google Scholar
• Robinson JG. Dalcetrapib: a review of Phase II data. Expert Opin. Invest. Drugs19, 795–805 (2010).
   PubMed Web of Science ®Google Scholar
• Franceschini G, Sirtori CR, Capurso A 2nd et al. A-IMilano apoprotein. Decreased high density lipoprotein cholesterol levels with significant lipoprotein modifications and without clinical atherosclerosis in an Italian family. J. Clin. Invest.66, 892–900 (1980).
   PubMed Web of Science ®Google Scholar
• Franceschini G, Calabresi L, Chiesa G et al. Increased cholesterol efflux potential of sera from ApoA-IMilano carriers and transgenic mice. Arterioscler. Thromb. Vasc. Biol.19, 1257–1262 (1999).
   PubMed Web of Science ®Google Scholar
• Shah PK, Yano J, Reyes O et al. High-dose recombinant Apolipoprotein A-IMilano mobilizes tissue cholesterol and rapidly reduces plaque lipid and macrophage content in Apolipoprotein E-deficient mice: potential implications for acute plaque stabilization. Circulation103, 3047–3050 (2001).
   PubMed Web of Science ®Google Scholar
• Ibanez B, Vilahur G, Cimmino G et al. Rapid change in plaque size, composition, and molecular footprint after recombinant apolipoprotein A-I Milano (ETC-216) administration: magnetic resonance imaging study in an experimental model of atherosclerosis. J. Am. Coll. Cardiol.51, 1104–1109 (2008).
   PubMed Web of Science ®Google Scholar
• Navab M, Anantharamaiah GM, Reddy ST et al. Apolipoprotein A-I mimetic peptides. Arterioscler. Thromb. Vasc. Biol.25, 1325–1331 (2005).
   PubMed Web of Science ®Google Scholar
• Navab M, Anantharamaiah GM, Hama S et al. Oral administration of an Apo A-I mimetic peptide synthesized from D-amino acids dramatically reduces atherosclerosis in mice independent of plasma cholesterol. Circulation105, 290–292 (2002).
   PubMed Web of Science ®Google Scholar
• Zheng L, Nukuna B, Brennan M-L et al. Apolipoprotein A-I is a selective target for myeloperoxidase-catalyzed oxidation and functional impairment in subjects with cardiovascular disease. J. Clin. Invest.114, 529–541 (2004).
   PubMed Web of Science ®Google Scholar
• Hansel B, Giral P, Nobecourt E et al. metabolic syndrome is associated with elevated oxidative stress and dysfunctional dense high-density lipoprotein particles displaying impaired antioxidative activity. J. Clin. Endocrinol. Metab.89, 4963–4971 (2004).
   PubMed Web of Science ®Google Scholar
• Navab M, Reddy ST, Van Lenten BJ et al. The role of dysfunctional HDL in atherosclerosis. J. Lipid. Res.50(Suppl.), S145–S149 (2009).
   PubMedGoogle Scholar
• de la Llera Moya M, Atger V, Paul JL et al. A cell culture system for screening human serum for ability to promote cellular cholesterol efflux. Relations between serum components and efflux, esterification, and transfer. Arterioscler. Thromb.14, 1056–1065 (1994).
   Google Scholar
• Zhang Y, Zanotti I, Reilly MP et al. Overexpression of Apolipoprotein A-I promotes reverse transport of cholesterol from macrophages to feces in vivo. Circulation108, 661–663 (2003).
   PubMed Web of Science ®Google Scholar
• Navab M, Hama SY, Hough GP et al. A cell-free assay for detecting HDL that is dysfunctional in preventing the formation of or inactivating oxidized phospholipids. J. Lipid. Res.42, 1308–1317 (2001).
   PubMed Web of Science ®Google Scholar
• Ansell BJ, Navab M, Hama S et al. Inflammatory/antiinflammatory properties of high-density lipoprotein distinguish patients from control subjects better than high-density lipoprotein cholesterol levels and are favorably affected by simvastatin treatment. Circulation108, 2751–2756 (2003).
   PubMed Web of Science ®Google Scholar
• Navab M, Anantharamaiah GM, Reddy ST et al. Mechanisms of disease: proatherogenic HDL – an evolving field. Nat. Clin. Pract. Endocrinol. Metab.2, 504–511 (2006).
   PubMedGoogle Scholar